Proactive Investors - Run By Investors For Investors

NetScientific says portfolio company Glycotest receives initial US$3mln tranche from Fosun Pharma

The group said the initial tranche will primarily serve to drive Glycotest's proprietary HCC Panel towards commercialisation in the US and to transfer the technology to Fosun
IP
Netscientific added that funding of the remaining US$7mln is due on completion of certain milestones

NetScientific PLC (LON:NSCI) revealed that its portfolio company Glycotest Inc. has received the initial US$3mln tranche of the US$10mln Series A financing round with Shanghai Fosun Pharmaceutical Co. Ltd., a leading healthcare group based in China.

The AIM-listed transatlantic healthcare IP commercialisation group, said the initial tranche will primarily serve to drive Glycotest's proprietary HCC Panel towards commercialisation in the US and to transfer the technology to Fosun Pharma, who will commercialise it in China.

READ: NetScientific says continuing to assess all remaining strategic options after closing formal sale process

It added that funding of the remaining US$7mln is due on completion of certain milestones.

NetScientific's chief executive officer and chairman of Glycotest Inc., Francois R. Martelet commented: "The receipt of the first tranche of financing will kickstart Glycotest's commercialisation activities and moves them closer to becoming the first company to commercialise an assay for the early detection and surveillance of early-stage liver cancer, where there is a huge unmet need.

“We are proud that Glycotest's ongoing efforts are materialising into tangible results and look forward to the progress to come."

View full NSCI profile View Profile

Netscientific PLC Timeline

Related Articles

Antigens
November 29 2018
The deal with New England Biolabs, signed in October, is expected to secure six-figure royalty sums as soon as next year
Hep C
November 22 2018
The company made positive operational progress in the year to June 30.
1538160791_petri-dishes.jpg
September 28 2018
The biotech group revealed it had brought in $9.1mln via an oversubscribed placing

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use